Onconetix Inc (ONCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Onconetix Inc (ONCO) has a cash flow conversion efficiency ratio of -0.181x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($11.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ONCO market cap for the company's overall valuation and market capitalisation.
Onconetix Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Onconetix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Onconetix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Onconetix Inc ranked by their cash flow conversion efficiency. Explore ONCO operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
-0.054x |
|
Creo Medical Group PLC
LSE:CREO
|
-0.684x |
|
Lucky Minerals Inc
V:LKY
|
0.000x |
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
-0.015x |
|
Upgrade Invest Nordic AB
ST:UPGRAD
|
N/A |
|
Biodexa Pharmaceticals
NASDAQ:BDRX
|
-0.204x |
|
Midsona AB (publ)
ST:MSON-A
|
0.048x |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
0.172x |
Annual Cash Flow Conversion Efficiency for Onconetix Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Onconetix Inc from 2019 to 2025. View Onconetix Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.77 Million | $-9.68 Million | -0.614x | +43.79% |
| 2024-12-31 | $9.61 Million | $-10.50 Million | -1.092x | +88.71% |
| 2023-12-31 | $1.40 Million | $-13.58 Million | -9.670x | -2395.38% |
| 2022-12-31 | $22.39 Million | $-8.68 Million | -0.388x | +72.58% |
| 2021-12-31 | $1.45 Million | $-2.04 Million | -1.413x | -286.65% |
| 2020-12-31 | $4.73 Million | $-1.73 Million | -0.365x | -165.70% |
| 2019-12-31 | $6.00 Million | $-825.13K | -0.138x | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more